Abstract
Interleukin 6 and C-reactive protein (CRP) were determined prior to IL-2 therapy in sera from metastatic melanoma patients. Patients with elevated serum IL-6 (> 20 pg ml-1) and/or CRP (> 10 mg l-1) levels were associated with resistance to IL-2 therapy. A correlation between high serum IL-6 levels and a shorter median survival was also observed.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Tartour, E., Dorval, T., Mosseri, V. et al. Serum interleukin 6 and C-reactive protein levels correlate with resistance to IL-2 therapy and poor survival in melanoma patients. Br J Cancer 69, 911–913 (1994). https://doi.org/10.1038/bjc.1994.175
Issue Date:
DOI: https://doi.org/10.1038/bjc.1994.175
This article is cited by
-
STAT3 transcription factor as target for anti-cancer therapy
Pharmacological Reports (2020)
-
Pathway-based dissection of the genomic heterogeneity of cancer hallmarks’ acquisition with SLAPenrich
Scientific Reports (2018)
-
Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma
Journal for ImmunoTherapy of Cancer (2015)
-
Prognostic significance of the modified Glasgow prognostic score in elderly patients with gastric cancer
Journal of Gastroenterology (2014)
-
Protein and non-protein biomarkers in melanoma: a critical update
Amino Acids (2012)
